BioAtla(BCAB) - 2024 Q3 - Quarterly Results

BIOATLA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of approximately 9 months (ongoing) in a heavily pretreated population; actionable feedback received from the U.S. Food and Drug Administration (the "FDA") regarding our proposed pivotal trial in second-line (2L) plus SCCHN – Evalstotug ...